OBJECTIVES: An important factor to take into account when evaluating the effectiveness of a drug is adherence. Adherence describes the degree to which a patient correctly follows medical advice. The objective of this study was to evaluate the factors that determine adherence of adult patients with type 2 diabetes treated with once-daily injectable liraglutide 1.8mg or twice-daily injectable exenatide 10g. METHODS: A retrospective study was conducted employing US data from the IMS PharMetrics claims database. The index period ranged from January 2010 to December 2010 and patients needed to be continuously enrolled 12 months before and after the index date. Patients were treatment naïve to liraglutide and exenatide but may not have been injection-naïve as prior insulin use was not part of the patient selection exclusion criteria, which may have impacted the outcomes as a limitation of the study. Adherence was measured by continuous Medication Possession Ratio (MPR) as well as a categorical response using MPR (MPRՆ80%ϭhigh adherence and MPRϽ80%ϭlow adherence). The determinants of adherence were estimated using multivariable models and bivariate testing was conducted for selection of the possible predictors. Covariates were then included and a stepwise model-building approach was used. RESULTS: Data from 3623 patients (2036 liraglutide 1.8mg and 1587 exenatide 10g) were used in the analyses. When adjusting for confounding effects, patients treated with exenatide 10g were approximately 11% (pϽ.0001) less adherent than patients treated with liraglutide 1.8mg assessed by the continuous MPR measure. The odds ratio (OR) for achieving a high categorical MPR for liraglutide 1.8mg compared to exenatide 10g was 1.33 in favor of liraglutide 1.8mg (pϽ.0001). Variables found to impact the level of adherence were age, gender, the geographic region, treatment, and percentage co-payment from the claimant. CONCLUSIONS: The analysis showed that once-daily liraglutide 1.8mg is associated with better adherence than twice-daily exenatide 10g.
PDB53 PRELIMINARY RESULTS OF A MULTICENTER OBSERVATIONAL STUDY OF TREATMENT COMPLIANCE WITH FREE-COMBINATION VERSUS FIXED COMBINATION TREATMENT IN TYPE II DIABETES MELLITUS PATIENTS IN GREECE (LESS STUDY)
Rombopoulos G 1 , Hatzikou M 1 , Kossiva E 1 , Athanasiadis A 2 , Elisaf M 3 1 Novartis Hellas, Metamorfosis, Greece, 2 Foundation for Economic and Industrial Research (IOBE), Athens, Greece, 3 University Hospital of Ioannina, Ioannina, Greece OBJECTIVES: To assess the differences in the compliance of Greek patients suffering from Type 2 diabetes mellitus who receive free combination therapy of metformin and vildagliptin compared to the diabetic patients who receive fixed combination therapy of metformin/vildagliptin. METHODS: Eight hundred adult patients inadequately controlled on twice daily 850mg metformin monotherapy who were recently added vildagliptin treatment as add on to metformin (fixed dose combination or free combination) were enrolled in the study. The observation period was 6 months. Upon treatment initiation each patient received a diary, in which they had to record their treatment on a daily basis. The diary then was returned to the physician at the final visit. Additionally, at baseline and at the last visit of the study, patients were asked to complete a questionnaire related to their compliance of their indicated treatment. Patients were defined as compliant when they hadn't missed any drug dose, received the correct dosage of the medication and did not interrupt their treatment. RESULTS: The preliminary results the overall study sample 63% were considered to be compliant. In the between groups analysis, it was found that 56% of patients receiving free combination were compliant with their treatment compared to a substantially higher 68% of compliant patients in the fixed combination group (pϽ0,005). Odds Ratio was equal to 1,647, suggesting that patients receiving free combination were 1.647 times more likely not to comply with their treatment than the patients on fixed combination. A statistically significant reduction in Hb1Ac was observed in both groups between the first and last visit (pϽ0,001) but not any difference between two groups, which is attributed to the short follow-up period. CONCLUSIONS: Patients on fixed dose combination treatment for Type II Diabetes are more compliant than patients on free dose combinations. Improved compliance has been shown to improve disease management, which can prevent expensive complications. 
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PDB55 THE ADAPTATION OF THE INJECTION PEN ASSESSMENT QUESTIONNAIRE FOR USE IN EUROPE -VALIDATION RESULTS FROM A LARGE MULTICENTER STUDY OF RECOMBINANT HUMAN GROWTH HORMONE TREATMENT NAÏVE CHILDREN AND ADULTS
Pleil A 1 , Kimel M 2 , Wollmann H 3 1 Pfizer, Inc., San Diego, CA, USA, 2 United BioSource Corporation, Bethesda, MD, USA, 3 Pfizer, Ltd, Walton Oaks, UK OBJECTIVES: To examine the reliability and validity of the Injection Pen Assessment Questionnaire (IPAQ) in a European population. METHODS: The IPAQ is a 29-item measure of objective and comparative ease of use and preference for recombinant human growth hormone (rhGH) injection devices based on content elicited from focus groups and one-on-one interviews of device users. The IPAQ was included in a Phase 3, open-label, multicenter trial in 136 experienced rhGH subjects (parent-child dyads) in the United States to test the ease of use and preference for a new Genotropin® disposable pen (NCT00965484). IPAQ content was adapted for use in adults and translated into seven languages. Data from a Phase 3, open-label, multicenter, crossover study (NCT01112865; Nϭ120) was used to evaluate the psychometric properties of the IPAQ in a mixed sample of dyadic pairs, adult subjects and caregivers of pediatric subjects. Analyses were conducted by group and total sample. RESULTS: Confirmatory factor analysis provided evidence for a second order factor solution for four subscales and a total IPAQ score; and supported the conceptual framework developed from previous qualitative and quantitative research. Although IPAQ subscales did not consistently meet acceptable internal consistency reliability for some group level comparisons, the total IPAQ score showed high internal consistency for both pens (Cronbach's alpha ϭ 0.77 -0.86). In general, the construct validation (predictive validity) findings were consistent across pens and across subject groups and generally consistent with those from the US trial. CONCLUSIONS: The IPAQ total score for ease of use demonstrated good internal consistency reliability and good construct validity in measuring ease of use with injection pens to administer rhGH. Findings from this research are consistent with those from the US-based study, supporting the usefulness of the IPAQ total score in evaluating ease of use and preference for injection pens in clinical trials and in practice. 
PDB56 DEVELOPMENT AND VALIDATION OF PATIENT REPORTED ENDPOINTS FOR T2DM
OBJECTIVES:
There are no existing patient reported outcome (PRO) measures in Type 2 Diabetes Mellitus (T2DM) developed in accordance with FDA Guidance on PROs. The objective of this study was to develop and validate a T2DM-specific PRO measure examining hypoglycemic symptoms (HS), weight neutrality (WN), medication tolerability (MT), and medication compliance (MC). METHODS: The Diabetes-Management and Impact Questionnaire (D-MIQ) and the Diabetes-Assessment of Blood Sugar Questionnaire (D-ABS) were developed in three phases: concept elicitation (CE; nϭ20), item generation, and cognitive interviews (CIs; nϭ20). The D-ABS was finalized as a 36-item PRO assessing HS with a yes/no response scale measuring symptom frequency and an 11-point numeric response scale measuring symptom severity. The D-MIQ was finalized as an 18-item PRO measuring impacts of HS, WN, MT, and MC, with four-and five-point Likert-type response scales and a yes/no scale. Following content validation, a stand-alone observational study was conducted in 100 subjects to assess the psychometric properties of the D-MIQ and D-ABS. RESULTS: Subjects had a mean age of 57.4 (SD 12.6) years (52% female, 60% white). All items on the D-ABS and D-MIQ showed good convergent validity with A503 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
